227 related articles for article (PubMed ID: 24530815)
1. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
[TBL] [Abstract][Full Text] [Related]
3. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
[TBL] [Abstract][Full Text] [Related]
4. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Raja FA; Griffin CL; Qian W; Hirte H; Parmar MK; Swart AM; Ledermann JA
Br J Cancer; 2011 Sep; 105(7):884-9. PubMed ID: 21878941
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
[TBL] [Abstract][Full Text] [Related]
6. Optimal treatment of early-stage ovarian cancer.
Collinson F; Qian W; Fossati R; Lissoni A; Williams C; Parmar M; Ledermann J; Colombo N; Swart A;
Ann Oncol; 2014 Jun; 25(6):1165-71. PubMed ID: 24631948
[TBL] [Abstract][Full Text] [Related]
7. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
9. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.
Banerjee S; Rustin G; Paul J; Williams C; Pledge S; Gabra H; Skailes G; Lamont A; Hindley A; Goss G; Gilby E; Hogg M; Harper P; Kipps E; Lewsley LA; Hall M; Vasey P; Kaye SB
Ann Oncol; 2013 Mar; 24(3):679-87. PubMed ID: 23041585
[TBL] [Abstract][Full Text] [Related]
11. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
Champer M; Huang Y; Hou JY; Tergas AI; Burke WM; Hillyer GC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Jan; 148(1):19-27. PubMed ID: 29153542
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
Marchetti C; Kristeleit R; McCormack M; Mould T; Olaitan A; Widschwendter M; MacDonald N; Ledermann JA
Gynecol Oncol; 2017 Jan; 144(1):57-60. PubMed ID: 27825669
[TBL] [Abstract][Full Text] [Related]
13. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
[TBL] [Abstract][Full Text] [Related]
14. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
Raja FA; Counsell N; Colombo N; Pfisterer J; du Bois A; Parmar MK; Vergote IB; Gonzalez-Martin A; Alberts DS; Plante M; Torri V; Ledermann JA
Ann Oncol; 2013 Dec; 24(12):3028-34. PubMed ID: 24190964
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Eng KH; Hanlon BM; Bradley WH; Szender JB
Gynecol Oncol; 2015 Nov; 139(2):228-35. PubMed ID: 26383827
[TBL] [Abstract][Full Text] [Related]
16. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM
Gynecol Oncol; 2023 Jun; 173():130-137. PubMed ID: 37148580
[TBL] [Abstract][Full Text] [Related]
17. Doublet chemotherapy in the elderly patient with ovarian cancer.
Teo MY; Power DG; Tew WP; Lichtman SM
Oncologist; 2012; 17(11):1450-60. PubMed ID: 22915061
[TBL] [Abstract][Full Text] [Related]
18. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):802-808. PubMed ID: 38008497
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study.
Tian C; Sargent DJ; Krivak TC; Powell MA; Gabrin MJ; Brower SL; Coleman RL
Br J Cancer; 2014 Aug; 111(5):843-50. PubMed ID: 25003664
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
Chen T; Xu J; Xia B; Wang H; Shen Y
J Gynecol Oncol; 2024 Jan; 35(1):e22. PubMed ID: 37945326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]